Savara (SVRA) said Friday it has launched an Early Access Program for molgramostim, allowing physicians of eligible patients with autoimmune pulmonary alveolar proteinosis to request the investigational inhalation solution in select regions where it is not yet commercially available.
The program has been reviewed and allowed to proceed by the US Food and Drug Administration, and is expected to expand through 2026, Savara said, adding it aims to complete a Biologics License Application submission for molgramostim as a treatment for aPAP to the FDA in H1 2025.
Shares of the company were up nearly 1% in recent Friday premarket activity.
Price: 4.2800, Change: +0.04, Percent Change: +0.94
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。